Spots Global Cancer Trial Database for Study of XL999 in Patients With Metastatic Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of XL999 in Patients With Metastatic Colorectal Cancer
Official Title: A Phase 2 Study of XL999 Administered Intravenously to Subjects With Metastatic Colorectal Cancer
Study ID: NCT00277303
Conditions
Interventions
Study Description
Brief Summary: This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic colorectal cancer (CRC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
California Cancer Care, Inc., Greenbrae, California, United States
Integrated Community Oncology Network; Division of Clinical Research, Jacksonville, Florida, United States
Hematology Oncology Associated of the Treasure Coast, Port St. Lucie, Florida, United States
University of Chicago, Chicago, Illinois, United States
Joliet Oncology-Hematology Associated, Ltd., Joliet, Illinois, United States
Indiana University Cancer Center, Indianapolis, Indiana, United States
Hematology Oncology Associates of Rockland, PC, New City, New York, United States
Center for Oncology Research and Treatment, PA, Dallas, Texas, United States
Contact Details
Name: Lynne Bui, MD
Affiliation: Exelixis
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
